Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.
Schneider S, Blick G, Burke C, Ward D, Benson P, Felizarta F, Green D, Donovan C, Harper G, Merrill D, Metzner AA, Mycock K, Wallis H, Patarroyo J, Brogan AP, Oglesby A.
Schneider S, et al. Among authors: benson p.
Infect Dis Ther. 2024 Apr;13(4):891-906. doi: 10.1007/s40121-024-00961-y. Epub 2024 Apr 3.
Infect Dis Ther. 2024.
PMID: 38570443
Free PMC article.